- Home
- E vs ARGX Comparison
E vs ARGX Comparison
Compare E & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- E
- ARGX
- Stock Information
- Founded
- E 1953
- ARGX 2008
- Country
- E Italy
- ARGX Netherlands
- Employees
- E N/A
- ARGX N/A
- Industry
- E Oil & Gas Production
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- E Energy
- ARGX Health Care
- Exchange
- E Nasdaq
- ARGX Nasdaq
- Market Cap
- E 42.6B
- ARGX 37.3B
- IPO Year
- E 1995
- ARGX 2017
- Fundamental
- Price
- E $26.38
- ARGX $623.82
- Analyst Decision
- E Buy
- ARGX Strong Buy
- Analyst Count
- E 6
- ARGX 20
- Target Price
- E $39.60
- ARGX $634.50
- AVG Volume (30 Days)
- E 331.3K
- ARGX 290.3K
- Earning Date
- E 02-14-2025
- ARGX 10-31-2024
- Dividend Yield
- E 8.24%
- ARGX N/A
- EPS Growth
- E N/A
- ARGX N/A
- EPS
- E 0.85
- ARGX N/A
- Revenue
- E $102,822,886,419.00
- ARGX $1,908,659,000.00
- Revenue This Year
- E N/A
- ARGX $61.99
- Revenue Next Year
- E N/A
- ARGX $42.48
- P/E Ratio
- E $15.18
- ARGX N/A
- Revenue Growth
- E N/A
- ARGX 85.56
- 52 Week Low
- E $26.12
- ARGX $349.86
- 52 Week High
- E $34.30
- ARGX $644.97
- Technical
- Relative Strength Index (RSI)
- E 22.75
- ARGX 58.04
- Support Level
- E $28.10
- ARGX $613.95
- Resistance Level
- E $27.06
- ARGX $644.97
- Average True Range (ATR)
- E 0.34
- ARGX 14.33
- MACD
- E -0.12
- ARGX -0.42
- Stochastic Oscillator
- E 10.07
- ARGX 50.28
About E ENI S.p.A.
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2023, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2023, Eni held reserves of 6.4 billion barrels of oil equivalent, 48% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity called Plentitude, which it will likely list publicly at some point.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.